Quick Answer
OptimizeRx Corp reported Cash and Equivalents of $23.36 million for fiscal year 2025.
OptimizeRx Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $23.36M | +74.6% |
| 2024 | $13.38M | -3.4% |
| 2023 | $13.85M | -23.9% |
| 2022 | $18.21M | -78.5% |
| 2021 | $84.68M | +705.2% |
| 2020 | $10.52M | -44.2% |
| 2019 | $18.85M | +111.5% |
| 2018 | $8.91M | +74.0% |
| 2017 | $5.12M | -27.2% |
| 2016 | $7.03M | -14.3% |
| 2015 | $8.21M | +138.1% |
| 2014 | $3.45M | +208.2% |
| 2013 | $1.12M | +293.4% |
| 2012 | $284.3K | -70.4% |
| 2011 | $959.2K | -25.0% |
| 2010 | $1.28M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $19.52M | +21.0% | +17.7% |
| June 30, 2025 | $16.59M | — | +0.1% |
| March 31, 2025 | $16.57M | — | +23.9% |
| December 31, 2024 | $13.38M | -3.4% | -17.0% |
| September 30, 2024 | $16.13M | — | +16.4% |
| December 31, 2023 | $13.85M | -23.9% | +41.2% |
| June 30, 2023 | $9.81M | -88.8% | -40.4% |
| March 31, 2023 | $16.44M | -81.5% | -9.7% |
- OptimizeRx Corp showed an increase of +74.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, OptimizeRx Corp’s cash and equivalents has grown by 1728.1% (from $1.28 million to $23.36 million).
- The most recent figure is from OptimizeRx Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: